Background: It has been demonstrated that individual cognitive behaviour therapy is an effective treatment for chronic fatigue syndrome (CFS). The aim of the present study was to investigate the effectiveness of cognitive behaviour group therapy (CBGT) in an unselected group of CFS patients. Additionally, pretreatment characteristics of CFS patients who improve after CBGT were explored. Methods: In a non-randomised waiting list controlled design, 31 patients were allocated to CBGT and 36 to the waiting list condition. CBGT consisted of 12 two-hour sessions during 6 months. Main outcome measures were fatigue (Checklist Individual Strength) and functional impairment (Sickness Impact Profile). Results: A moderate effect on fatigue in favour of CBGT was found. For functional impairment, the effect was opposite to what was expected. Patients who improved after CBGT had less complaints at baseline compared to patients who did not improve. Conclusions: An explanation for the moderate effect might be that during CBGT, rest and relaxation were too much emphasised. Furthermore, an unselected group of CFS patients and therapists inexperienced in CB(G)T for CFS participated. Suggestions to improve CBGT for future research are given.

Keywords:
Cognitive behaviour group therapy, Chronic fatigue syndrome
1.
Fukuda K, Strauss SE, Hicki I, Sharpe MC, Dobbins JG, Komaroff A, the International Chronic Fatigue Study Group: The chronic fatigue syndrome: A comprehensive approach to its definition and study. Ann Intern Med 1994;121:953–959.
2.
Vercoulen JHMM, Swanink CMA, Galama JMD, Fennis JFM, Jongen PJH, Hommes OR, van der Meer JWM, Bleijenberg G: The persistence of fatigue in chronic fatigue syndrome and multiple sclerosis: The development of a model. J Psychosom Res 1998;45:507–517.
3.
Deale A, David AS: Chronic fatigue syndrome: Evaluation and management. J Neuropsychiatry Clin Neurosci 1994;6:189–194.
4.
Surawy C, Hackmann A, Hawton K, Sharpe M: Chronic fatigue syndrome: A cognitive approach. Behav Res Ther 1995;33:535–544.
5.
Sharpe M: Cognitive behavior therapy for chronic fatigue syndrome: Efficacy and implications. Am J Med 1998;105:104S–109S.
6.
Prins J, Bleijenberg G: Cognitive behavior therapy for chronic fatigue syndrome: A case study. J Behav Ther Exp Psychiatry 1999;30:325–339.
7.
Butler S, Chalder T, Ron M, Wessely S: Cognitive behaviour therapy in chronic fatigue syndrome. J Neurol Neurosurg Psychiatry 1991;54:153–158.
8.
Deale A, Chalder T, Marks I, Wessely S: Cognitive behaviour therapy for chronic fatigue syndrome: A randomized controlled trial. Am J Psychol 1997;154:408–414.
9.
Prins JB, Bleijenberg G, Bazelmans E, Elving LD, de Boo TM, Severens JL, van der Wilt GJ, Spinhoven P, van der Meer JWM: Cognitive behaviour therapy for chronic fatigue syndrome: A multicenter randomised controlled trial. Lancet 2001;357:841–847.
10.
Sharpe M, Hawton K, Simkin S, Suraway C, Hackman A, Klimes I, Peto T, Warell D, Seagroatt V: Cognitive behaviour therapy for the chronic fatigue syndrome: A randomised controlled trial. BMJ 1996;312:22–26.
11.
Bonner D, Ron M, Chalder T, Butler S, Wessely S: Chronic fatigue syndrome: A follow-up study. J Neurol Neurosurg Psychiatry 1994;57:617–621.
12.
Deale A, Husain K, Chalder T, Wessely S: Long-term outcome of cognitive behavior therapy versus relaxation therapy for chronic fatigue syndrome: A 5-year follow-up study. Am J Psychiatry 2001;158:2038–2042.
13.
Price JR, Couper J: Cognitive behavior therapy for adults with chronic fatigue syndrome (Cochrane Review); in: Cochrane Library, Issue 3, 2000. Update Software.
14.
Reid S, Chalder T, Cleare AJ, Hotopf M, Wessely S: Chronic fatigue syndrome; Clinical review. BMJ 2000;320:292–296.
15.
Whiting P, Bagnall AM, Sowden AJ, Cornell JE, Mulrow CD, Ramírez G: Interventions for the treatment and management of chronic fatigue syndrome. A systematic review. JAMA 2001;286:1360–1368.
16.
Chalder T, Butler C, Wessely S: In-patient treatment of chronic fatigue syndrome. Behav Cogn Psychother 1996;24:351–365.
17.
Cox DL, Findley LJ: Management of chronic fatigue syndrome in an inpatient setting: Presentation of an approach and perceived outcome. Br J Occup Ther 1998;61:405–409.
18.
Marlin RG, Anchel H, Gibson JC, Goldberg WM, Swinton M: An evaluation of multidisciplinary intervention for chronic fatigue syndrome with long-term follow-up, and a comparison with untreated controls. Am J Med 1998;105:110S–114S.
19.
Akagi H, Klimes I, Bass C: Cognitive behavioral therapy for chronic fatigue syndrome in a general hospital – Feasible and effective. Gen Hosp Psychiatry 2001;23:254–260.
20.
Chalder T, Tong J, Deary V: Family cognitive behaviour therapy for chronic fatigue syndrome: An uncontrolled study. Arch Dis Child 2002;86:95–97.
21.
Söderberg S, Evengård B: Short-term group therapy for patients with chronic fatigue syndrome. Psychother Psychosom 2001;70:108–111
22.
Vercoulen JHMM, Swanink CMA, Fennis JFM, Galama JMD, van der Meer JWM, Bleijenberg G: Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 1994;38:383–392.
23.
Bergner M, Bobbit RA, Carter WB, Gilson BS: The sickness impact profile: Development and final revision of a health status measure. Med Care 1981;19:787–805.
24.
Vercoulen JHMM, Swanink CMA, Zitman FG, Vreden SGS, Hoofs MPE, Fennis JFM, Galama JMD, van der Meer JWM, Bleijenberg G: A randomised double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 1996;347:858–861.
25.
Arrindell WA, Ettema JHM: SCL-90, handleiding bij een multidimensionele psychopathologie-indicator. Lisse, Swets & Zeitlinger BV, 1986.
26.
Beck AT, Steer RA, Garbin MG: Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev 1988;8:77–100.
27.
Vercoulen JHMM, Hommes OR, Swanink CMA, Jongen PJH, Fennis JFM, Galama JMD, van der Meer JWM, Bleijenberg G: The measurement of fatigue in multiple sclerosis: A comparison with patients with chronic fatigue syndrome and healthy subjects. Arch Neurol 1996;53:642–649.
28.
Vercoulen JHMM, Swanink CMA, Galama JMD, Fennis JFM, van der Meer JWM, Bleijenberg G: Prognosis in chronic fatigue syndrome: A prospective study on the natural course. J Neurol Neurosurg Psychiatry 1996;60:489–494.
29.
Prins JB, Bazelmans E, van der Werf S, van der Meer JWM, Bleijenberg G: Cognitive behaviour therapy for chronic fatigue syndrome: predictors of treatment outcome; in Sivik T, Byrne D, Lipsitt DR, Christodoulou GN, Dienstfrey H (eds): Psycho-Neuro-Endocrino-Immunology (PNEI), a Common Language for the Whole Human Body. Amsterdam, Elsevier, 2002, 1241, pp 131–135.
30.
Bazelmans E, Prins JB, Hoogveld S, Bleijenberg G: Manual-based cognitive behaviour therapy for chronic fatigue syndrome: therapists’ adherence and perceptions. Cogn Behav Ther 2004;33:143–150.
31.
Van Houdenhove B, Neerinckx E, Onghena P, Vingerhoets A, Lysens R, Vertommen H: Daily hassles reported by chronic fatigue syndrome and fibromyalgia patients in tertiary care: A controlled quantitative and qualitative study. Psychother Psychosom 2002;71:207–213.
32.
Prins JB, Bos E, Huibers MJH, Servaes P, van der Werf SP, van der Meer JWM, Bleijenberg G: Social support and the persistence of complaints in chronic fatigue syndrome. Psychother Psychosom 2004;73:174–182.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.